The “Infliximab– Biosimilar Insight, 2021” report from DelveInsight gives detailed information on 35+ companies and 45+ marketed and pipeline therapies in the Infliximab Biosimilars market. It also includes clinical and nonclinical stage products, as well as commercial and pipeline medication profiles.
Some Key Highlights from the Infliximab Biosimilar Insight Report
There are currently 35+ major companies including Janssen Biotech,Celltrion, Pfizer, Genor Biopharma, Samsung Bioepis, Prestige BioPharma and Sandoz working in the Infliximab Biosimilar market landscape.
Merck launched a biosimilar of Remicade (infliximab), a blockbuster immune-mediated inflammatory diseases medication, in the United States in July 2017, while Janssen Biotech markets the drug domestically.
Inflectra (infliximab-dyyb) (Celltrion/Pfizer) was approved by the US Food and Drug Administration in April 2016 for all qualifying indications of the reference product, Remicade® (Infliximab). This is the second biosimilar approved by the FDA.
GB 242 (Genor Biopharma), Ixifi (Pfizer), SB2 (Samsung Bioepis), PBP 1505 (Prestige BioPharma), Zessly (Sandoz), others are among the Infliximab Biosimilar emerging drugs.
Learn more by requesting sample @ Infliximab Biosimilar Insight
Infliximab (Remicade): Product Overview
Infliximab is a chimeric monoclonal antibody that is used to treat a variety of autoimmune diseases. It is offered under the brand names Remicade and others.
Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease are among the conditions that fall under this category.
Infliximab Biosimilar Marketed Drug Product Profile
Inflectra is a biosimilar to Remicade (Infliximab), a reference biologic. The therapy has been approved for the treatment of adults and children (ages six and above) with moderate to severe active Crohn’s disease who have had a poor response to conventional therapy, adults with moderate to severe active ulcerative colitis who have not responded to conventional therapy; moderate to severe active rheumatoid arthritis in combination with methotrexate; active ankylosing spondylitis; active psoriatic arthritis; and chronic severe plaque psoriasis.
Infliximab Biosimilar Emerging Drug Product Profile
GB 242: Genor Biopharma
Genor Biopharma (a Walvax Biotechnology affiliate) is working on a biosimilar of Infliximab called GB 242 for the treatment of autoimmune disorders and rheumatoid arthritis. For the treatment of Rheumatoid Arthritis, the drug is now in phase III development.
Research and Development in the GB 242 Biosimilar Landscape
NCT04178850: A Randomized, Double-blind, Multi-center Phase III Comparative Study to Evaluate the Efficacy and Safety of Recombinant Human-mouse Chimeric Anti-TNF-alpha Monoclonal Antibody for Injection was launched by Genor Biopharma in October 2017. The proportion of individuals who attained ACR20 at week 30 in the two groups is compared in this study.
For more insights visit Infliximab Biosimilar Marketed and Emerging Drugs
Infliximab Biosimilar Major Players
Infliximab Biosimilar Therapeutics Assessment
By Product Type
By Route of Administration
By Molecule Type
Stem Cell Therapy
Scope of the Report
Infliximab Biosimilar Key Players: Janssen Biotech, Celltrion/Pfizer and Genor Biopharma, among others
Table of Contents
Infliximab Biosimilars: Snapshot
Regulatory Outlook For Biosimilars
Infliximab (Reference Product: Remicade)
Infliximab Biosimilar Research and Development
Remicade Biosimilar: Emerging Opportunities
Infliximab: Biosimilars Assessment
Infliximab Biosimilars Profiles: By Company
Infliximab Biosimilars: Comparative Landscape: By Company
Infliximab Biosimilars: Competitive Landscape
Infliximab Biosimilars Market Drivers
Infliximab Biosimilars Market Barriers
Infliximab Biosimilars SWOT Analysis
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Etanercept Biosimilar Insights
Get comprehensive analysis of Etanercept pipeline drugs and key companies including Sandoz, Samsung Bioepis, Reliance Life Sciences, Probiomed, Pfizer, Merck, Cipla, Biocon, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States